248 related articles for article (PubMed ID: 37167084)
21. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Shanmugam V; Margolskee E; Kluk M; Giorgadze T; Orazi A
Head Neck Pathol; 2016 Sep; 10(3):394-9. PubMed ID: 26922062
[TBL] [Abstract][Full Text] [Related]
22. [Rosai-Dorfman disease: clinicopathologic, immunohistochemical and etiologic study of 16 cases].
Yu JB; Liu WP; Zuo Z; Tang Y; Liao DY; Ji H; Bai YQ; Li SH; Lu CQ; Luo HB
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):33-8. PubMed ID: 17374236
[TBL] [Abstract][Full Text] [Related]
23. Rosai-Dorfman-Destombes disease - histiocytic disorder with inflammatory manifestation.
Adam Z; Adamová Z; Pour L; Řehák Z; Koukalová R; Král Z
Klin Onkol; 2022; 35(4):262-170. PubMed ID: 35989082
[TBL] [Abstract][Full Text] [Related]
24. [Cutaneous Rosai-Dorfman disease with lack of BRAF-V600, KRAS or NRAS mutations: A reactive or neoplastic disorder?].
Machado I; Alcacer Fernández-Coronado J; Requena C; Través V; Latorre Martínez N; Ortega J; Requena L; Alcacer García J
Rev Esp Patol; 2022; 55(1):52-56. PubMed ID: 34980442
[TBL] [Abstract][Full Text] [Related]
25. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours.
Ungureanu IA; Cohen-Aubart F; Héritier S; Haroche J; Donadieu J; Emile JF
Histopathology; 2023 Aug; 83(2):320-325. PubMed ID: 37012662
[TBL] [Abstract][Full Text] [Related]
26. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
27. Neurological Manifestations of Histiocytic Disorders.
Banks SA; Sartori Valinotti JC; Go RS; Abeykoon JP; Goyal G; Young JR; Koster MJ; Vassallo R; Ryu JH; Davidge-Pitts CJ; Ravindran A; Bennani NN; Shah MV; Rech KL; Tobin WO;
Curr Neurol Neurosci Rep; 2023 Jun; 23(6):277-286. PubMed ID: 37209319
[TBL] [Abstract][Full Text] [Related]
28. Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation.
Garces S; Yin CC; Patel KP; Khoury JD; Manning JT; Li S; Xu J; Pina-Oviedo S; Johnson MR; González S; Molgó M; Ruiz-Cordero R; Medeiros LJ
Mod Pathol; 2019 Jan; 32(1):16-26. PubMed ID: 30323237
[TBL] [Abstract][Full Text] [Related]
29. Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease.
Baraban E; Sadigh S; Rosenbaum J; Van Arnam J; Bogusz AM; Mehr C; Bagg A
Br J Haematol; 2019 Sep; 186(6):837-844. PubMed ID: 31172509
[TBL] [Abstract][Full Text] [Related]
30. Isolated intracranial rosai-dorfman disease involving the meninges: report of a rare case.
Bhat A; Kupanur SS; Geethamani V
Turk Neurosurg; 2015; 25(1):186-9. PubMed ID: 25640569
[TBL] [Abstract][Full Text] [Related]
31. Rosai-Dorfman disease of the breast: a clinicoradiologic and pathologic study.
Wang Q; Bradley K; Zhang M; Li S; Li X
Hum Pathol; 2023 Nov; 141():30-42. PubMed ID: 37673345
[TBL] [Abstract][Full Text] [Related]
32. Primary intraosseous Rosai-Dorfman disease: An analysis of clinicopathologic characteristics, molecular genetics, and prognostic features.
Weng X; Yang Y; Zhang M; Cai C; Sun Y; Wu X; Zhang R; Gui H; Li W; Xu Q; Liu X
Front Oncol; 2022; 12():950114. PubMed ID: 36185213
[TBL] [Abstract][Full Text] [Related]
33. [Histiocytosis of Rosai-Dorfman-Destombes extranodal of the jawbone: Report of a case and review of the literature].
Vaquier L; Abitbol C; Emile JF; Dossier A; Guyard A; Hourseau M
Ann Pathol; 2022 Apr; 42(3):264-268. PubMed ID: 35033363
[TBL] [Abstract][Full Text] [Related]
34. Cerebral manifestation and diagnostic dilemma of Rosai-Dorfman disease.
Almási S; Pancsa T; Tiszlavicz L; Sejben A
CNS Oncol; 2023 Dec; 12(4):CNS103. PubMed ID: 37551608
[TBL] [Abstract][Full Text] [Related]
35. Co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: possible relationship of two histiocytic disorders in rare cases.
O'Malley DP; Duong A; Barry TS; Chen S; Hibbard MK; Ferry JA; Hasserjian RP; Thompson MA; Richardson MS; Jaffe R; Sidhu JS; Banks PM
Mod Pathol; 2010 Dec; 23(12):1616-23. PubMed ID: 20729813
[TBL] [Abstract][Full Text] [Related]
36. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.
Abla O; Jacobsen E; Picarsic J; Krenova Z; Jaffe R; Emile JF; Durham BH; Braier J; Charlotte F; Donadieu J; Cohen-Aubart F; Rodriguez-Galindo C; Allen C; Whitlock JA; Weitzman S; McClain KL; Haroche J; Diamond EL
Blood; 2018 Jun; 131(26):2877-2890. PubMed ID: 29720485
[TBL] [Abstract][Full Text] [Related]
37. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract][Full Text] [Related]
38. Case report of intracranial Rosai-Dorfman disease.
Wahba M
Hosp Pract (1995); 2013; 41(4):83-6. PubMed ID: 24145594
[TBL] [Abstract][Full Text] [Related]
39. Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.
Salama HA; Jazieh AR; Alhejazi AY; Absi A; Alshieban S; Alzahrani M; Alaskar A; Gmati G; Damlaj M; Abuelgasim KA; Alghamdi A; Alahmari B; Almugairi A; Alzahrani H; Bazarbachi A; Musa MOH; Goyal G
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e66-e75. PubMed ID: 32943371
[TBL] [Abstract][Full Text] [Related]
40. A lethal intracranial Rosai-Dorfman disease of the brainstem diagnosed at autopsy.
Imada H; Sakatani T; Sawada M; Matsuura T; Fukushima N; Nakano I
Pathol Int; 2015 Oct; 65(10):549-53. PubMed ID: 26184902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
